the Fourth Hospital of Hebei Medical University — Shijiazhuang

Public research footprint of the Fourth Hospital of Hebei Medical University, compiled from the ClinicalTrials.gov public registry.

216

Registered studies

128

Active

Recruiting now

Completed

Stopped or withdrawn

Most-studied conditions

Follicular Lymphoma · HR-positive, HER2-negative Metastatic Breast Cancer With Brain… · Unresectable or Metastatic Gastric or Gastroesophageal Junction… · Diffuse Large B Cell Lymphoma

Recently updated registry entries

NCT04613596 — Phase 2 Trial of Adagrasib Monotherapy and in Combination With Pembrolizumab and a Phase… (Recruiting)
NCT07127822 — Assessing Iparomlimab and Tuvonralimab in Recurrent or Metastatic MSI-H/dMMR Gastric… (Recruiting)
NCT07744932 — SABR Combined With Axitinib and Toripalimab for Oligometastatic Renal Cell Carcinoma (Recruiting)

7 more recent registry entries at this facility

Enter your work email to view the full list.

I’d also like to receive occasional marketing emails from Eichor for research sites (optional — unsubscribe anytime).

Work at the Fourth Hospital of Hebei Medical University?

Verify and correct how your facility appears in public registry records — free.

Verify this profile →

Compiled from public registry records (ClinicalTrials.gov) as of August 05, 2026. Counts reflect how this facility appears in registry listings; name variants may exist and are not combined. This page describes public records only and makes no assessment of any facility.